THU062 PRESTO 3: A Simulated-use Study Assessing Preferences Of Nurses In The USA And Europe Between Two Lanreotide Syringes (Somatuline Autogel Vs Pharmathen)
Authors: Williams Jessica , Ferone Diego , Martin Wendy , Houchard Aude , Pommie Christelle , Ribeiro-Oliveira Antonio , Grossman Ashley 
Published: October 2023

Abstract
Disclosure: J. Williams: None. D. Ferone: Advisory Board Member; Self; Novartis-AAA, Recordati, Camurus, Sandoz. Speaker; Self; Novartis-AAA, Recordati, Camurus, Sandoz. W. Martin: Speaker; Self; Ipsen, Speaker, Advanced Accelerator Applications. A. Houchard: Employee; Self; Ipsen. Stock Owner; Self; Ipsen. C. Pommie: Employee; Self; Ipsen. Stock Owner; Self; Ipsen. A. Ribeiro-Oliveira: Employee; Self; Ipsen. Stock Owner; Self; Ipsen. A. Grossman: None.
Introduction/Background: Somatostatin analogs (SSAs), such as octreotide and lanreotide depot formulations, are common treatments for patients with neuroendocrine tumors (NETs) and acromegaly. The Pharmathen syringe is now available in Europe and the USA for lanreotide depot injection. It is important for decision making when using SSAs that there is confidence in, and ease of use, with any syringe. Aims: PRESTO 3 compared nurses’ preference for the Somatuline Autogel syringe vs the Pharmathen syringe after injection-pad testing. We also evaluate whether any regional differences were observed for European and US nurse subgroups. Materials and Methods: This international simulated-use study included oncology/endocrinology nurses with ≥1 year experience in managing NETs/acromegaly. Each nurse tested both syringes twice, in random order, before completing an electronic preference survey. The primary endpoint was whether there was any overall preference (%, 95% CI) for the Somatuline Autogel syringe vs the Pharmathen syringe, assessed using a one-sample exact binomial test. Secondary objectives included rating and assessing the importance of 11 syringe attributes for Europe and the USA. Results: In total, 94 nurses were enrolled: 72.3% in Europe (mean age 39.1 [SD, 11.1] years) and 27.7% in the USA (mean age, 46.0 [SD, 11.3] years). In Europe and the USA, nurses were experienced in injecting patients with NETs (63.2% and 69.2%, respectively), acromegaly (5.9% and 11.5%) or both diseases (30.9% and 19.2%). Overall, 86.2% (CI 77.5%–92.4%) of nurses expressed a preference (67.0% ‘strong’, 19.1% ‘slight’) for the Somatuline Autogel syringe vs the Pharmathen syringe (p&lt;0.0001). Results were similar between regions, with 85.3% (Europe) and 88.5% (USA) of nurses preferring the Somatuline Autogel syringe over the Pharmathen syringe (both p&lt;0.0001). Regardless of the region (Europe/USA), performance rating was higher with the Somatuline Autogel syringe vs the Pharmathen syringe for all attributes except ‘confidence that needle appears patient-friendly’ and ‘confidence of a low risk of needle-stick injuries’ (p&lt;0.05). The two attributes considered the most important when injecting patients in routine clinical practice in both regions were ‘easy to use from preparation to injection’ (Europe, 33.8%; USA, 23.1%) and ‘comfortable to handle during use from preparation to injection’ (Europe, 16.2%; USA, 30.8%). The attribute considered least important was ‘fast administration from preparation to injection’ (Europe, 26.5%; USA, 26.9%). Conclusions: This simulated-use study showed that nurses both in the USA and Europe strongly preferred the user experience of the Somatuline Autogel syringe over the Pharmathen syringe, and ranked the Somatuline Autogel syringe more highly across almost all attributes. Ease of use and handling comfort were considered the most important to nurses in both regions.
Presentation: Thursday, June 15, 2023